Vemurafenib increases miR-31-5p in keratinocyte-derived exosomes, which suppresses ALKBH1 and elevates RNA m6A in melanoma cells, thereby promoting proliferation and reducing vemurafenib sensitivity. Targeting the miR-31-5p/ALKBH1 axis and m6A modification may offer a potential therapeutic strategy to enhance vemurafenib sensitivity in BRAFV600E melanoma cells.

1 day ago

Journal

MIR31 (MicroRNA 31)

BRAF V600E

Zelboraf (vemurafenib)

Successful treatment of hairy cell leukemia with TP53 abnormality using cladribine combined with low-dose rituximab: a case report and literature review. (PubMed, Anticancer Drugs)

This case suggests that the combination of cladribine and low-dose rituximab may be an effective therapeutic strategy for classical HCL with TP53 abnormality, enabling deep molecular response and reversal of associated bone marrow fibrosis. Further prospective studies are warranted to validate these findings.

1 day ago

Journal

BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53)

TP53 mutation • BRAF V600E • BRAF V600 • TP53 deletion

Rituxan (rituximab) • cladribine

Molecular findings in thyroid tumors: Practical diagnostic, prognostic, and therapeutic insights. (PubMed, Semin Diagn Pathol)

In each molecular category, secondary alterations can occur; most notably TERT promoter and TP53 mutations occur with increasing frequency in high-grade differentiated, poorly differentiated, and anaplastic thyroid carcinomas. This article will review the diagnostic, prognostic, and therapeutic significance of molecular alterations across the spectrum of follicular cell derived thyroid tumors and discuss strategies for investigating unusual molecular alterations encountered in clinical practice.

1 day ago

Review • Journal

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • TERT (Telomerase Reverse Transcriptase)

TP53 mutation • BRAF V600E • BRAF V600 • FGFR2 mutation • FGFR2 fusion • ALK fusion

Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine. (PubMed, Phys Med)

The median AD was significantly higher in the BRAFp.V600E mutated DTC lesions than in the RAS mutated DTC lesions. BRAFp.V600E mutated DTC lesions with a partial and complete response received significantly higher doses than other lesions.

1 day ago

Journal

RAS (Rat Sarcoma Virus)

BRAF V600E • BRAF V600 • RAS mutation

Mekinist (trametinib) • Tafinlar (dabrafenib)

A Primary Dedifferentiated Melanoma, Masquerading as a Soft Tissue Sarcoma, Displaying BRAF p.V600E, CDKN2A, TP53, and TERT Promoter Mutations. (PubMed, Int J Surg Pathol)

These tumors are relatively aggressive and often associated with multiple mutations, including those associated with their aggressive clinical behavior. A review of similar reported tumors in the literature is discussed herewith.

1 day ago

Journal

BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • SOX10 (SRY-Box 10) • PRAME (Preferentially Expressed Antigen In Melanoma)

BRAF V600E • BRAF V600

Clinicopathological profile of high-grade differentiated thyroid carcinoma in Indonesian tertiary hospital. (PubMed, J Pathol Transl Med)

HGDTC presents with more aggressive characteristics and a worse prognosis. Accurate diagnosis, molecular profiling, and long-term monitoring are essential for optimal management.

1 day ago

Journal

TERT (Telomerase Reverse Transcriptase)

BRAF V600E • BRAF V600

Ultrarapid BRAF mutation detection on supernatant cell-free DNA obtained by FNA: An accurate and expedient method for BRAF assessment in aggressive thyroid carcinomas. (PubMed, Cancer Cytopathol)

The Idylla BRAF assay delivers ultrarapid results that are both reliable and accurate with high success rates, particularly on ScfDNA samples. ScfDNA samples also have the fastest TAT because no histologic processing or pre-extraction are required for testing.

1 day ago

Journal

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF mutation • BRAF V600

The fascinating history of papillary thyroid carcinoma nuclei: revelation of two nuclear morphologies-"Classical papillary" and "papillary-like", with different pathobiologic characteristics. (PubMed, Cancer Cytopathol)

The story has come full circle, and the recent proposal to incorporate FVPTC into follicular adenoma is in keeping with Lindsay's original concept. By the current understanding, these nuclei are classified better by molecular associations.

1 day ago

Review • Journal

BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)

BRAF V600E • BRAF V600 • RAS mutation

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)

P1, N=267, Recruiting, Pfizer | Trial completion date: May 2030 --> Aug 2030 | Trial primary completion date: Nov 2028 --> Feb 2029

1 day ago

Trial completion date • Trial primary completion date

BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)

BRAF V600E • MSI-H/dMMR

Erbitux (cetuximab) • 5-fluorouracil • Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • claturafenib (PF-07799933) • midazolam hydrochloride

Firmonertinib for Adjuvant Therapy in Completely Resected Stage IA EGFR-Mutated NSCLC (ChiCTR2600121611)

P4, N=535, Recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital

2 days ago

New P4 trial • Real-world evidence

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • NRG1 (Neuregulin 1) • BRCA (Breast cancer early onset)

TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • ALK positive • RET fusion • ALK fusion • FGFR mutation • RET mutation • ROS1 fusion • MET mutation • RB1 mutation • NRG1 fusion • KRAS G12 • BRCA mutation

Ivesa (firmonertinib)

A prospective, single-arm clinical study of QL1706 monotherapy in elderly patients with driver gene-negative, PD-L1-positive NSCLC (ChiCTR2600121140)

P=N/A, N=40, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University

2 days ago

New trial

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation

PD-L1 IHC 22C3 pharmDx

Qibeian (iparomlimab/tuvonralimab)

An Open-Label, Dose-Escalation, Multiple Administration, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Anti-tumor Activity of TH-CART-027 Cell Injection in Subjects with Recurrent or Progressive Grade 4 Glioma (ChiCTR2600119774)

P=N/A, N=21, Shanghai Tongji Hospital; Shanghai Tongji Hospital

2 days ago

New trial

BRAF (B-raf proto-oncogene) • CD276 (CD276 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • BRAF V600 • NTRK fusion